Evidence map›Paper›PMID 26998692›Full record

ArticleNature genetics2016

Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes.

James Dooley, Lei Tian, Susann Schonefeldt, Viviane Delghingaro-Augusto, Josselyn E Garcia-Perez, Emanuela Pasciuto, Daniele Di Marino, Edward J Carr, Nikolay Oskolkov, Valeriya Lyssenko and 19 more

Abstract read
In one paragraph

Article in Nature genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. The influence of ICAM1 rs5498 on diabetes mellitus risk: evidence from a meta-analysis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Genetics of type-1 diabetes.Diabetology international · 2024
    Review
  20. Circulating pancreatic enzyme levels are a causal biomarker of type 1 diabetes.medRxiv : the preprint server for health sciences · 2024
    Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 12 institutions in 8 countries.

James DooleyCenter for the Biology of Disease, VIB, Leuven, Belgium.
Lei TianCenter for the Biology of Disease, VIB, Leuven, Belgium.
Susann SchonefeldtCenter for the Biology of Disease, VIB, Leuven, Belgium.
Viviane Delghingaro-AugustoAustralian National University Medical School, Canberra, Australian Capital Territory, Australia.
Josselyn E Garcia-PerezCenter for the Biology of Disease, VIB, Leuven, Belgium.ORCID 0000-0003-2369-532X
Emanuela PasciutoCenter for the Biology of Disease, VIB, Leuven, Belgium.
Daniele Di MarinoDepartment of Informatics, Università della Svizzera Italiana, Lugano, Switzerland.
Edward J CarrLymphocyte Signaling and Development Institute Strategic Programme, Babraham Institute, Cambridge, UK.
Nikolay OskolkovDepartment of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden.
Valeriya LyssenkoDepartment of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden.
Dean FranckaertCenter for the Biology of Disease, VIB, Leuven, Belgium.
Vasiliki LagouCenter for the Biology of Disease, VIB, Leuven, Belgium.
Lut OverberghDepartment of Clinical and Experimental Medicine, University of Leuven, Leuven, Belgium.
Jonathan VandenbusscheDepartment of Medical Protein Research, VIB, Ghent, Belgium.
Joke AllemeerschVIB Nucleomics Core, University of Leuven, Leuven, Belgium.
Genevieve Chabot-RoyImmunology-Oncology Section, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
Jane E DahlstromAustralian National University Medical School, Canberra, Australian Capital Territory, Australia.
D Ross LaybuttGarvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia.
Nikolai PetrovskyDepartment of Endocrinology, Flinders University, Adelaide, South Australia, Australia.
Luis SochaJohn Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia.
Kris GevaertDepartment of Medical Protein Research, VIB, Ghent, Belgium.
Anton M JettenImmunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, US National Institutes of Health, Research Triangle Park, North Carolina, USA.
Diether LambrechtsVesalius Research Center, VIB, Leuven, Belgium.
Michelle A LintermanLymphocyte Signaling and Development Institute Strategic Programme, Babraham Institute, Cambridge, UK.
Chris C GoodnowGarvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia.
Christopher J NolanAustralian National University Medical School, Canberra, Australian Capital Territory, Australia.
Sylvie LesageImmunology-Oncology Section, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.ORCID 0000-0002-0968-2795
Susan M SchlennerCenter for the Biology of Disease, VIB, Leuven, Belgium.
Adrian ListonCenter for the Biology of Disease, VIB, Leuven, Belgium.
VIB-KU Leuven Center for Cancer Biology · BEAustralian National University · AUKU Leuven · BEBabraham Institute · GBGarvan Institute of Medical Research · AUGhent University · BEHôpital Maisonneuve-Rosemont · CAFlinders University · AULund University · SENational Institutes of Health · USSteno Diabetes Centers · DKUniversità della Svizzera italiana · CH

Funding

Mechanism Of Action And Functions Of The Gli-related Proteins Glis 1-3ZIAES100485 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI JETTEN, ANTON M · 2009 to 2025
$35.9M
Mechanism Of Action And Functions Of The Gli-related Proteins Glis 1-3Z01ES100485 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI JETTEN, ANTON M · 2002 to 2008
$2.3M
Biotechnology and Biological Sciences Research Council BBS/E/B/000C0409Intramural NIH HHS Z01 ES100485
6 · The paper itself

Abstract

Type 1 (T1D) and type 2 (T2D) diabetes share pathophysiological characteristics, yet mechanistic links have remained elusive. T1D results from autoimmune destruction of pancreatic beta cells, whereas beta cell failure in T2D is delayed and progressive. Here we find a new genetic component of diabetes susceptibility in T1D non-obese diabetic (NOD) mice, identifying immune-independent beta cell fragility. Genetic variation in Xrcc4 and Glis3 alters the response of NOD beta cells to unfolded protein stress, enhancing the apoptotic and senescent fates. The same transcriptional relationships were observed in human islets, demonstrating the role of beta cell fragility in genetic predisposition to diabetes.

Indexed as

Genetic Predisposition to DiseaseAnimalsApoptosisCellular SenescenceDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2DietDNA-Binding ProteinsFemaleGene Expression RegulationHumansInsulin-Secreting CellsMaleMiceMice, Inbred C57BLMice, Inbred NODDNA-Binding ProteinsGlis3 protein, mouseRepressor ProteinsTrans-ActivatorsXRCC4 protein, mouse

Identifiers

PMID26998692
PMCPMC5584070
OpenAlexW2311083859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.